Clinical trial · Interventional
PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer
Clinical Evaluation of PET-MRI Versus PET-CT in Pediatric Oncology Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pilot clinical trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI) works compared to PET/computed tomography (CT) in diagnosing younger patients with cancer. PET/MRI and PET/CT are procedures that combine the pictures from a PET scan and an MRI scan or a CT scan. The PET and MRI scans or PET and CT scans are done at the same time with the same machine. The combined scans give more detailed pictures of areas inside the body than either scan gives by itself. It is not yet known whether PET/MRI works better than PET/CT in diagnosing younger patients with cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Childhood Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| computed tomography | Procedure | — | UNRESOLVED |
| fludeoxyglucose F 18 | Radiation | — | UNRESOLVED |
| magnetic resonance imaging | Procedure | — | UNRESOLVED |
| positron emission tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (fludeoxyglucose F 18 PET/CT and PET/MRI)
- description
- Patients undergo fludeoxyglucose F 18 PET/CT followed by PET/MRI.
- interventionNames
- Radiation: fludeoxyglucose F 18
- Procedure: positron emission tomography
- Procedure: computed tomography
- Procedure: magnetic resonance imaging
Primary outcomes (2)
- measure
- Diagnostic Accuracy of PET/MRI
- timeFrame
- 1 day
- description
- Evaluation of the PET/MR imaging platform will be based on the ability to detect lesions. Evaluation of each lesion will be recorded using the following 5 point rating scale: 1=benign, 2=probably benign, 3=indeterminate, 4=probably malignant, 5=malignant. A Wilcoxon (Mann-Whitney) rank-sum test and two-sided z-test will be used to compare diagnostic accuracy of PET/MRI with PET/CT.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who are referred by their physician for clinically indicated diagnostic fludeoxyglucose F 18 (18F-FDG) PET/CT (with or without clinically indicated diagnostic MRI) * Subjects with malignancies including hematologic disorders * Subjects NOT requiring sedation or anesthesia * Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging) Exclusion Criteria: * Subjects who are unable or unwilling to give their assent to both examinations if \> 7 years old * Subjects requiring general anesthesia or sedation in order to undergo PET/CT or MRI * Subjects unable to undergo magnetic resonance (MR) scanning due to exclusion by University Hospitals-Case Medical Center restriction policies for Magnetic Resonance Imaging (UHCMC MRI restriction policies) as mentioned in the standard UHCMC MRI informed consent form * Previously known allergies against MRI contrast agents (exclusion criterion only for contrast enhanced MRI) * Pregnant or breast feeding subjects, as determined by standard questionnaire administered prior to scanning
References
Publications (0)
Data not yet available